Market Place
Sourcing Support
Adicet Bio Reports Q4 & Full Year 2025 Financial Result
12 Mar 2026 //
BUSSINESSWIRE
Adicet Bio Announces Q2 2025 Financial Results & Business Updates
07 Aug 2025 //
BUSINESSWIRE
Adicet Bio to Join Chat at 45th Canaccord Genuity Conference
05 Aug 2025 //
BUSINESSWIRE
Adicet Bio Reports Q1 2025 Financial Results and Business Updates
06 May 2025 //
BUSINESSWIRE
Adicet Bio Appoints Michael Grissinger to the Board of Directors
17 Apr 2025 //
BUSINESSWIRE
Adicet Bio to Join 2025 Canaccord Genuity Oncology Conference
31 Mar 2025 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grant under Nasdaq LR 5635(c)(4)
31 Dec 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 Jul 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28 Jun 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 May 2024 //
BUSINESSWIRE
Adicet Reports Q1 2024 Results, Business Updates
14 May 2024 //
BUSINESSWIRE
Adicet Bio At Citizens JMP Life Sciences Conference
07 May 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
30 Apr 2024 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
28 Mar 2024 //
BUSINESSWIRE
Adicet Reports4Q FYR 2023 & Highlights Recent Company Progress
19 Mar 2024 //
BUSINESSWIRE
Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright Conference
11 Mar 2024 //
BUSINESSWIRE
Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering
25 Jan 2024 //
BUSINESSWIRE
Adicet Bio, Inc. Announces Proposed Public Offering
22 Jan 2024 //
PRESS RELEASE
Adicet Bio, Inc. Announces Pricing of Public Offering
22 Jan 2024 //
BUSINESSWIRE
Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024
04 Jan 2024 //
BUSINESSWIRE
Adicet Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
BUSINESSWIRE
Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference
07 Nov 2023 //
BUSINESSWIRE
Adicet to Present Posters Highlighting Allogeneic Gamma Delta T Cell Platform
27 Sep 2023 //
BUSINESSWIRE
Adicet Reports Second Quarter 2023 Financial Results & Provides Business Updates
09 Aug 2023 //
BUSINESSWIRE
Adicet Reports1Q 2023 FYR and Provides Business Updates
09 May 2023 //
BUSINESSWIRE
Adicet Bio to Present at the 2023 JMP Securities Life Sciences Conference
09 May 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28 Apr 2023 //
BUSINESSWIRE
Adicet to Participate in 2023 Canaccord Genuity Horizons in Oncology Conference
13 Apr 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 Mar 2023 //
BUSINESSWIRE
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28 Feb 2023 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
31 Jan 2023 //
BUSINESSWIRE
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial
10 Dec 2022 //
BUSINESSWIRE
Adicet Bio to Host Investor Webcast to Discuss Data from Ongoing ADI-001
02 Dec 2022 //
BUSINESSWIRE
Adicet Bio to Present at the Virtual JMP Securities Hematology Oncology Summit
30 Nov 2022 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
30 Nov 2022 //
BUSINESSWIRE
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President
29 Nov 2022 //
BUSINESSWIRE
Adicet Reports3Q 2022 Financial Results and Provides Business Updates
08 Nov 2022 //
BUSINESSWIRE
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs
07 Nov 2022 //
BUSINESSWIRE
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
01 Nov 2022 //
BUSINESSWIRE
Adicet Bio to Present at Upcoming Investor Conferences
07 Sep 2022 //
BUSINESSWIRE
Adicet Reports Second Quarter 2022 Financial Results
10 Aug 2022 //
BUSINESS WIRE
Adicet Bio to Present at Upcoming Investor Conferences
21 Jun 2022 //
BUSINESSWIRE
Adicet`s gamma delta CAR-T therapy readout tees up phase 2 trial
06 Jun 2022 //
FIERCEBIOTECH
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03 Jun 2022 //
BUSINESSWIRE
Adicet Bio Reports Positive Clinical Update from ADI-001 PI Trial in NHL
26 May 2022 //
BUSINESSWIRE
Adicet Bio to Present at Upcoming Investor Conferences
18 May 2022 //
BUSINESSWIRE
Adicet Reports Q1 2022 Financial Results and Provides Business Updates
12 May 2022 //
BUSINESSWIRE
Adicet Presents Preclinical Data at the ISCT Annual Meeting
05 May 2022 //
BUSINESSWIRE
Adicet Bio Announces Oral Presentation of Updated ADI-001 PI Data at ASCO
27 Apr 2022 //
BUSINESSWIRE
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
19 Apr 2022 //
BUSINESSWIRE
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2022 //
BUSINESSWIRE
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results
15 Mar 2022 //
PRESS RELEASE
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2022 //
PRESS RELEASE
Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering
10 Dec 2021 //
GLOBENEWSWIRE
Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock
08 Dec 2021 //
PRESS RELEASE
Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock
07 Dec 2021 //
GLOBENEWSWIRE
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic
06 Dec 2021 //
PRESS RELEASE
Adicet Bio to Host Webcast Presentation of ADI-001 Interim Clinical Data
29 Nov 2021 //
GLOBENEWSWIRE
Adicet Presents Preclinical Data for ADI-002 for Solid Tumors at SITC
12 Nov 2021 //
GLOBENEWSWIRE
